TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Postoperative Blood Loss After Surgery (Estimated Blood Loss (EBL))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post-operative 2 hr Hemoglobin (Hg) mg/dL Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post-operative 24-hr Hemoglobin (Hg) mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decrease in urine output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants with major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Ki, the influx constant that describes the rate of [18F]FDG uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distribution volume ratio (DVR) of [18F] ISO-1 uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of purchasing targeted products
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of gastric content regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Response to antiretroviral therapy (ARVs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NK Cell Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Cytokines Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total diagnostic yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Peak Oxygen Consumption (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Salivary Immunoglobulin A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Perceived frequency of cognitive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perceived severity of cognitive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Information processing speed and executive functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Female Sexual Function Index Desire Domain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SSE Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance to the protein-restricted diet
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in best corrected visual acuity (BCVA) by 15 letters or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final visual acuity resulting in Snellen equivalent of 20/200 or worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ,ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: CLR,ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of delayed gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in word fluency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in motor dexterity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative incidence of febrile neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Accrual Percentage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Altered circulating blood cell bioenergetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxidized plasma redox state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Alterations in resting energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Alterations in fatty acid oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Poor oxidative capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Predicting Type 2 Diabetes development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Average Pain on The Brief Pain Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of change in microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained virologic response (SVR24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Nocturnal enuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic capacity of the papillary biopsy technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dermatomal spread of sensory blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in the Profile of Mood States (POMS): Total Mood Disturbance (TMD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS): Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in the Hamilton Anxiety Scale (HAM-A): Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite neonatal outcome - any one of the following (for twins, either infant): Fetal or neonatal death
Endpoint domain: Mortality/survival
Primary endpoint: Documented sepsis within 72 hours of delivery
Endpoint domain: Adverse events/effects
Primary endpoint: Number of EEG identified arousals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with Pure Red Cell Aplasia (PRCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall clinical outcome of pure red cell aplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to return of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (AEs) All Causalities
Endpoint domain: Adverse events/effects
Primary endpoint: Food Consumption Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child height-for-age z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of physical intimate partner violence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of neurological complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Outcome of severe neurological complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cavernous tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to first subsequent treatment (TTFST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity level restrictions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Consistency of assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of Optical Coherence Tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Short term neurobehaviour status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Solution-Related Corneal Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in sustained attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in executive functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Micronuclei counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathologic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of functionally significant coronary stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Technical success with no complications
Endpoint domain: Adverse events/effects
Primary endpoint: Self report of any drug abuse and usage
Endpoint domain: Adverse events/effects
Primary endpoint: Urine drug test (also known as Urine drug screen or UDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fold rise in titer of anti-group 1 stalk-antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Correct identification of sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aneurysm Related Death
Endpoint domain: Mortality/survival
Primary endpoint: Presence of diaphragmatic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Isolated nodal failures
Endpoint domain: Mortality/survival
Primary endpoint: Ratio of asymptomatic immunized population
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in blood parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Jebsen-Taylor Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of SYO-1126 and Glivec
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of SYO-1126 and Glivec
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oscillary potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brachial Artery Reactivity % Flow Mediated Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sign questionnaire scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in auscultation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of Pain Intensity (SPID) Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feeding intolerance episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: CAST questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The incidence of atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The prevalence of atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The prevalence of diagnosed co-morbidities in people with and without atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Minimal Residual Disease (MRD) Assays
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Leakage Observed During Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Seroconversion (Hemagglutination (HAI) Assay)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion (Microneutralization (MN) Assay)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With a Spinal Pain NRS Score Below 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of urinary and/or serum levels of biomarker NGAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in MRI contrast enhancement (Ktrans)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of life measured by EQ5D questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Visual Ability (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in tear secretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in dry eye symptomology
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in mitochondrial DNA copy number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength assessed by isokinetic strength measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Z score for weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in X ray film
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Refractive error of both eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevated HCG Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: MI, unstable angina with urgent revascularization, stroke, and death for any cause
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of regenerated post-extraction sockets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engraftment of CD34+ Selected Blood Stem Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Completion of interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Exercise/nutritional adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serotonin Receptor 1A Binding Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With All Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Pulse Rate at Last On-treatment Assessment (LOTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Sitting Diastolic Blood Pressure (DBP) at Last On-treatment Assessment (LOTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Last On-treatment Assessment (LOTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in monthly outpatient antibiotic dispensation (DDD)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Visual Analogue Scale (VAS) for baseline pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standing/walking tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cortisol Dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Cytokine Blood Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Attention restoration
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in CESD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in biological markers in saliva samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in biological markers in hair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Short-form Questionnaire on Quality of Life in IBD (CCVEII-9)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in the MOOD questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Systemic Hypotensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in number of preventive services received
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of respiratory episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cumulative major adverse cardiac events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of rejections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of steroid-resistant rejections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Renal Function Test (Cys-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum amikacin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Assessment of Cancer Treatment - Blood/Marrow Transplant
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Caregiver Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cerebral blood flow increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral embolization outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency domain parameters of HRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Goal attainment scaling (GAS) of therapeutic interventions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Compliance judged by the child (CarQ Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Compliance judged by the parent (PARQ Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complication status
Endpoint domain: Adverse events/effects
Primary endpoint: Mean numbers of bacterial colony forming units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Helping Babies Breathe Objective Structured Clinical Exam (OSCE) B score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Treatment-emergent AEs (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Serious side effect expression rate
Endpoint domain: Adverse events/effects
Primary endpoint: Liver tissue fibrosis area ratio by liver biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Scar Appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to recurrent non-fatal decompensated heart failure major adverse cardiac events (HF-MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful Intubations on First Attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acetabular cup anteversion angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spielberger State Anxiety Inventory (STAI-S) change score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to Total Hip Replacement surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in total Urticaria Severity Score (USS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of very early/early stage HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: germline mutation assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Genetic outcomes
Primary endpoint: SNP genotyping assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Genetic outcomes
Primary endpoint: Compliance with tea intake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline SRQ-20 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: tolerance and anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: serum concentration of CTRP-1,3, or 9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in DNA Methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength assessment using the Medical Research Council scale (MRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength measurement using a Dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes